Taiwan · Delayed Price · Currency is TWD OK Biotech Statistics
Total Valuation
OK Biotech has a market cap or net worth of TWD 2.07 billion. The enterprise value is 2.90 billion.
| Market Cap | 2.07B |
| Enterprise Value | 2.90B |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
OK Biotech has 141.38 million shares outstanding. The number of shares has increased by 8.28% in one year.
| Current Share Class | 141.38M |
| Shares Outstanding | 141.38M |
| Shares Change (YoY) | +8.28% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 4.64% |
| Owned by Institutions (%) | 0.34% |
| Float | 108.52M |
Valuation Ratios
The trailing PE ratio is 31.02.
| PE Ratio | 31.02 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 0.82 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 21.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.70, with an EV/FCF ratio of -9.58.
| EV / Earnings | 42.23 |
| EV / Sales | 1.77 |
| EV / EBITDA | 16.70 |
| EV / EBIT | 33.18 |
| EV / FCF | -9.58 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.43.
| Current Ratio | 1.79 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | 6.29 |
| Debt / FCF | -3.58 |
| Interest Coverage | 8.72 |
Financial Efficiency
Return on equity (ROE) is 3.37% and return on invested capital (ROIC) is 2.43%.
| Return on Equity (ROE) | 3.37% |
| Return on Assets (ROA) | 1.47% |
| Return on Invested Capital (ROIC) | 2.43% |
| Return on Capital Employed (ROCE) | 2.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.62 |
Taxes
In the past 12 months, OK Biotech has paid 8.58 million in taxes.
| Income Tax | 8.58M |
| Effective Tax Rate | 9.29% |
Stock Price Statistics
The stock price has decreased by -26.75% in the last 52 weeks. The beta is 0.13, so OK Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -26.75% |
| 50-Day Moving Average | 14.86 |
| 200-Day Moving Average | 15.84 |
| Relative Strength Index (RSI) | 47.61 |
| Average Volume (20 Days) | 162,585 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OK Biotech had revenue of TWD 1.64 billion and earned 68.75 million in profits. Earnings per share was 0.47.
| Revenue | 1.64B |
| Gross Profit | 442.83M |
| Operating Income | 86.22M |
| Pretax Income | 92.31M |
| Net Income | 68.75M |
| EBITDA | 165.04M |
| EBIT | 86.22M |
| Earnings Per Share (EPS) | 0.47 |
Balance Sheet
The company has 315.84 million in cash and 1.09 billion in debt, with a net cash position of -769.47 million or -5.44 per share.
| Cash & Cash Equivalents | 315.84M |
| Total Debt | 1.09B |
| Net Cash | -769.47M |
| Net Cash Per Share | -5.44 |
| Equity (Book Value) | 2.52B |
| Book Value Per Share | 17.39 |
| Working Capital | 614.80M |
Cash Flow
In the last 12 months, operating cash flow was 95.36 million and capital expenditures -398.25 million, giving a free cash flow of -302.89 million.
| Operating Cash Flow | 95.36M |
| Capital Expenditures | -398.25M |
| Free Cash Flow | -302.89M |
| FCF Per Share | -2.14 |
Margins
Gross margin is 27.01%, with operating and profit margins of 5.26% and 4.19%.
| Gross Margin | 27.01% |
| Operating Margin | 5.26% |
| Pretax Margin | 5.63% |
| Profit Margin | 4.19% |
| EBITDA Margin | 10.07% |
| EBIT Margin | 5.26% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 2.05%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 2.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 127.85% |
| Buyback Yield | -8.28% |
| Shareholder Yield | -6.26% |
| Earnings Yield | 3.32% |
| FCF Yield | -14.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2023. It was a forward split with a ratio of 1.10213412.
| Last Split Date | Sep 6, 2023 |
| Split Type | Forward |
| Split Ratio | 1.10213412 |
Scores
OK Biotech has an Altman Z-Score of 1.97 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 5 |